Tempus AI CEO Eric Lefkofsky Sold $7.7M in March as 2026 Growth Expectations Stayed Hot
Tempus AI CEO Eric Lefkofsky sold roughly $7.7M of TEM stock in late March, but the transaction landed while Tempus was still carrying strong 2026 growth expectations and heavy analyst attention.
Tempus AI CEO and chairman Eric Lefkofsky reported a cluster of open-market sales worth about $7.7M across late-March filings. The visible Form 4 activity around Tempus AI (TEM) landed on 2026-03-26, and the filings matter because Tempus entered 2026 with positive adjusted EBITDA targets, strong diagnostics and data-business growth, and fresh analyst coverage focused on its AI-enabled healthcare platform.
What Happened
The late-March Form 4 activity showed repeated sale lines in TEM shares, with the largest lines clearing on March 26. The raw filings do not suggest a full exit; they show a monetization event against a still-large remaining stake.
| Date | Code | Action | Shares | Value | Shares After |
|---|---|---|---|---|---|
| 2026-03-26 | S | sold | 7,784 | $369K | 15789469 |
| 2026-03-26 | S | sold | 59,657 | $2.8M | 15797253 |
| 2026-03-26 | S | sold | 65,559 | $3.0M | 15856910 |
| 2026-03-26 | S | sold | 1,947 | $92K | 8875033 |
| 2026-03-26 | S | sold | 14,915 | $700K | 8876980 |
| 2026-03-26 | S | sold | 16,388 | $750K | 8891895 |
Why This Matters
When a founder-CEO sells into strength, the key question is whether the transaction contradicts the business narrative or simply monetizes a still-dominant ownership position. In this case, the latter interpretation fits better.
Recent company commentary and analyst notes pointed to strong 2026 expectations driven by diagnostics growth, data partnerships, and the market’s broader appetite for AI-healthcare stories.
Ownership Context
Form 4 and 13G data both point to continued control. Lefkofsky’s beneficial ownership remained substantial, so this is not an "exit" story.
The most relevant internal pages for following this story are LEFKOFSKY ERIC P and Tempus AI. Large disclosed holders include BAILLIE GIFFORD & CO, VANGUARD GROUP INC.
What To Watch Next
- Whether Tempus keeps adding commercial partnerships and data contracts that support the 2026 guidance frame.
- Whether future Form 4s show a one-off monetization window or a rolling selling cadence.
- How TEM trades around the next earnings print and AI-healthcare sentiment shifts.
Related Pages On 13F Insight
Tempus AI (TEM), Eric Lefkofsky, Nvidia (NVDA), HPE (HPE), BAILLIE GIFFORD & CO, VANGUARD GROUP INC
Bottom Line
The filing looks like monetization into strength, not abandonment. Tempus still has to prove the 2026 growth story, but the insider activity did not erase it.
Questions Readers Actually Ask
Did Eric Lefkofsky exit Tempus AI?
No. The filings show sales, but they do not show him abandoning the company or surrendering beneficial control.
Why does this sale matter?
Because it happened while Tempus was still trading on high-growth AI-health expectations, which makes the timing notable.
What should investors watch next?
Watch whether Tempus continues to hit its commercial and guidance milestones and whether insider selling becomes a repeated pattern.
Related Research
Explore all researchQ1 2026 13F filings are due May 15, 2026. Track Berkshire, Millennium, Bridgewater and more. See expected filing dates, AI/sector themes, and how to access data the moment it drops.
Mar 31, 2026
Israel Englander's multi-strategy giant allocated $34.15B to broad ETFs (IWM, IVV, QQQ, SPY) — the signature of pod-based beta hedging — while making outsized bets on WMT (+679% shares) and Bitcoin via IBIT.
Mar 30, 2026
Massachusetts Financial Services has seen AUM decline from $334B to $310B over 8 quarters — yet the 100-year-old fund is making its most aggressive portfolio rotation in years, slashing DXCM (-86%), TEAM (-80%), and VEEV (-78%) while piling into streaming and cloud.
Mar 30, 2026
Simplex Trading reported a $177.41B Q4 2025 13F, but the filing reads less like a stock portfolio and more like an options-heavy market-structure book. That distinction is the whole story.
Apr 1, 2026
Scotiabank's $131.31B investment arm entered 114 new positions in Q4 2025 while trimming its dominant internal fund by 25% — one of the most aggressive quarterly reshuffles among top-100 filers.
Mar 30, 2026